Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment

Current Opinion in Psychiatry

Volumn 19, Issue 3, 2006, Pages 299-306

  Dickerson, Bradford C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Functional magnetic resonance imaging; Mild cognitive impairment

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; BRAIN FUNCTION; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE SEVERITY; ELECTROENCEPHALOGRAM; HIPPOCAMPUS; HUMAN; MENTAL PERFORMANCE; NEOCORTEX; NEUROIMAGING; NEUROSCIENCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SCHIZOPHRENIA; TASK PERFORMANCE;

ACETYLCHOLINE; BRAIN; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SEVERITY OF ILLNESS INDEX;

EID: 33748138102     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000218602.25346.c6     Document Type: Review

References (94)

1. Kukull WA, Bowen JD. Dementia epidemiology. Med Clin North Am 2002; 86:573-590.
2. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289:210-216.
3. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351:56-67.
4. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5:677-685. An insightful review of three major approaches to the development of disease-modifying therapy for Alzheimer's disease.
5. Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2005; 2:348-360.
6. Scheff SW, Price DA, Schmitt FA, et al. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2005 [E-pub ahead of print]. The first postmortem human study demonstrating synapse loss in the hippocampal dentate gyrus in MCI and Alzheimer's disease. This investigation, which employed stereologic and electron microscopic techniques, demonstrated correlations between synapse number and cognitive test measures, but no correlation with Braak neuropathologic stage.
7. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298:789-791.
8. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004; 63:1155-1162.
9. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003; 302:830-834.
10. Albert MS. Memory decline: the boundary between aging and age-related disease. Ann Neurol 2002; 51:282-284.
11. Galvin JE, Powlishta KK, Wilkins K, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol 2005; 62:758-765. A longitudinal clinicopathologic study showing that clinical evaluation can detect subtle cognitive impairment that predicts dementia and Alzheimer's disease neuropathology.
12. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-194.
13. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256:240-246.
14. Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's Dement 2005; 1:55-66.
15. Blacker D. Mild cognitive impairment - no benefit from vitamin E, little from donepezil. N Engl J Med 2005; 352:2439-2441.
16. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58:397-405.
17. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308.
18. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004; 61:59-66.
19. Saykin AJ, Wishart HA. Mild cognitive impairment: conceptual issues and structural and functional brain correlates. Semin Clin Neuropsychiatry 2003; 8:12-30.
20. Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005; 65:404-411.
21. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64:834-841. This study reported that longitudinally defined MCI can result from multiple neuropathologic etiologies, including Alzheimer's disease and cerebrovascular disease.
22. Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56:27-35.
23. Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 1997; 48:1508-1510.
24. Daly E, Zaitchik D, Copeland M, et al. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 2000; 57:675-680.
25. Rentz DM, Huh TJ, Faust RR, et al. Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals. Neuropsychology 2004; 18:38-49. This study demonstrated that adjustment for standard measures of intelligence enables the detection of subtle neuropsychological deficits that may predict cognitive decline.
26. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30:113-121.
27. Gold PE. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 2003; 80:194-210.
28. Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99:459-496.
29. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2:1403.
30. Perry EK, Perry RH, Blessed G, et al. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1:189.
31. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215:1237-1239.
32. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163:495-529.
33. Herholz K. PET studies in dementia. Ann Nucl Med 2003; 17:79-89.
34. Shinotoh H, Namba H, Fukushi K, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000; 48:194-200.
35. Shinotoh H, Namba H, Fukushi K, et al. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer Dis Assoc Disord 2000; 14 (Suppl 1):S114-S118.
36. Herholz K, Weisenbach S, Zundorf G, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 2004; 21:136-143.
37. Herholz K, Bauer B, Wienhard K, et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J Neural Transm 2000; 107:1457-1468.
38. Herholz K, Weisenbach S, Kalbe E, et al. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 2005; 16:1431-1434. In-vivo human PET demonstration that cortical acetylcholinesterase activity is decreased in some, but not all, patients with MCI.
39. Nordberg A. Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. Prog Brain Res 2004; 145:301-310.
40. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 2002; 15:445-450.
41. Mesulam M, Shaw P, Mash D, et al. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004; 55:815-828. This is a pathologic study of longitudinally followed older adults demonstrating the presence of subtle tauopathic change in nucleus basalis neurons in patients with early cognitive impairment.
42. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 2004; 11:43-49.
43. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51:145-155.
44. Burock MA, Buckner RL, Woldorff MG, et al. Randomized event-related experimental designs allow for extremely rapid presentation rates using functional MRI. Neuroreport 1998; 9:3735-739.
45. Price CJ, Friston KJ. Scanning patients with tasks they can perform. Hum Brain Mapp 1999; 8:102-108.
46. Machielsen WC, Rombouts SA, Barkhof F, et al. FMRI of visual encoding: reproducibility of activation. Hum Brain Mapp 2000; 9:156-164.
47. Manoach DS, Halpern EF, Kramer TS, et al. Test-retest reliability of a functional MRI working memory paradigm in normal and schizophrenic subjects. Am J Psychiatry 2001; 158:955-958.
48. Sperling R, Greve D, Dale A, et al. Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci U S A 2002; 99:455-460.
49. Leslie RA, James MF. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 2000; 21:314-318.
50. Honey G, Bullmore E. Human pharmacological MRI. Trends Pharmacol Sci 2004; 25:366-374. Definitive review of recent advances in phMRI.
51. Mattay VS, Callicott JH, Bertolino A, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 2000; 12:268-275.
52. Thiel CM, Henson RN, Morris JS, et al. Pharmacological modulation of behavioral and neuronal correlates of repetition priming. J Neurosci 2001; 21:6846-6852.
53. Coull JT, Nobre AC, Frith CD. The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting. Cereb Cortex 2001; 11:73-84.
54. Goekoop R, Barkhof F, Duschek EJ, et al. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. Neuropsychopharmacology 2005 [E-pub ahead of print].
55. Goldstein JM, Jerram M, Poldrack R, et al. Hormonal cycle modulates arousal circuitry in women using functional magnetic resonance imaging. J Neurosci 2005; 25:9309-9316.
56. Gibbs SE, D'Esposito M. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn Affect Behav Neurosci 2005; 5:212-221. A phMRI study demonstrating that bromocriptine produced greater behavioral improvement in individuals with lower working-memory span, and that prefrontal activity was greater after bromocriptine in individuals with slower memory retrieval rates.
57. Breiter HC, Gollub RL, Weisskoff RM, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997; 19:591-611.
58. Kalin NH, Davidson RJ, Irwin W, et al. Functional magnetic resonance imaging studies of emotional processing in normal and depressed patients: effects of venlafaxine. J Clin Psychiatry 1997; 58 (Suppl 16):32-39.
59. Honey GD, Bullmore ET, Soni W, et al. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical anti-psychotic drugs in patients with schizophrenia. Proc Natl Acad Sci U S A 1999; 96:13432-13437.
60. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002; 51:156-164.
61. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004; 61:877-889. A phMRI study demonstrating that changes in pregenual cingulate and ventral striatal activation correlate with symptomatic improvement in depression after fluoxetine therapy.
62. Davidson RJ, Irwin W, Anderle MJ, et al. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003; 160:64-75.
63. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161:1798-1805.
64. Schon K, Atri A, Hasselmo ME, et al. Scopolamine reduces persistent activity related to long-term encoding in the parahippocampal gyrus during delayed matching in humans. J Neurosci 2005; 25:9112-9123.
65. Thiel CM, Henson RN, Dolan RJ. Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study. Neuropsychopharmacology 2002; 27:282-292.
66. Thiel CM, Bentley P, Dolan RJ. Effects of cholinergic enhancement on conditioning-related responses in human auditory cortex. Eur J Neurosci 2002; 16:2199-2206.
67. Thiel CM, Friston KJ, Dolan RJ. Cholinergic modulation of experience-dependent plasticity in human auditory cortex. Neuron 2002; 35:567-574.
68. Bentley P, Vuilleumier P, Thiel CM, et al. Effects of attention and emotion on repetition priming and their modulation by cholinergic enhancement. J Neurophysiol 2003; 90:1171-1181.
69. Wink AM, Bernard F, Salvador R, et al. Age and cholinergic effects on hemodynamics and functional coherence of human hippocampus. Neurobiol Aging 2005 [E-pub ahead of print]. The first phMRI study of cholinergic modulation in aging, demonstrating effects of scopolamine on hippocampal activity.
70. Rombouts SA, Barkhof F, Van Meel CS, et al. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 73:665-671.
71. Thiel CM. Cholinergic modulation of learning and memory in the human brain as detected with functional neuroimaging. Neurobiol Learn Mem 2003; 80:234-244.
72. D'Esposito M, Deouell LY, Gazzaley A. Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. Nat Rev Neurosci 2003; 4:863-872.
73. Buckner RL, Snyder AZ, Sanders AL, et al. Functional brain imaging of young, nondemented, and demented older adults. J Cogn Neurosci 2000; 12 (Suppl 2):24-34.
74. Tsukada H, Kakiuchi T, Ando I, et al. Regulation of cerebral blood flow response to somatosensory stimulation through the cholinergic system: a positron emission tomography study in unanesthetized monkeys. Brain Res 1997; 749:10-17.
75. McGaughy J, Koene RA, Eichenbaum H, et al. Cholinergic deafferentation of the entorhinal cortex in rats impairs encoding of novel but not familiar stimuli in a delayed nonmatch-to-sample task. J Neurosci 2005; 25:10273-10281.
76. Goekoop R, Rombouts SA, Jonker C, et al. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. Neuroimage 2004; 23:1450-1459.
77. Saykin AJ, Wishart HA, Rabin LA, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127 (Pt 7):1574-1583.
78. Sperling RA, Bates JF, Chua EF, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74:44-50.
79. Grady CL, McIntosh AR, Beig S, et al. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci 2003; 23:986-993.
80. Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58:750-757.
81. Johnson SC, Saykin AJ, Baxter LC, et al. The relationship between fMRI activation and cerebral atrophy: comparison of normal aging and Alzheimer disease. Neuroimage 2000; 11:179-187.
82. Rosen AC, Gabrieli JD, Stoub T, et al. Relating medial temporal lobe volume to frontal fMRI activation for memory encoding in older adults. Cortex 2005; 41:595-602.
83. Goekoop R, Scheltens P, Barkhof F, et al. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - a pharmacological fMRI study. Brain 2006; 129 (Pt 1):141-157.
84. Muller U, Suckling J, Zelaya F, et al. Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Psychopharmacology (Berl) 2005; 180:624-633. The first phMRI study with pharmacokinetic measures demonstrating an association between plasma levels of methylphenidate and changes in regional brain activation during a reaction time task.
85. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci U S A 2001; 98:676-682.
86. Lustig C, Snyder AZ, Bhakta M, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A 2003; 100:14504-14509.
87. Greicius MD, Srivastava G, Reiss AL, et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004; 101:4637-4642.
88. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25:7709-7717. An important conceptual paper showing the spatial correspondence between brain regions involved in the 'default-mode' resting network and memory retrieval tasks, and those affected in Alzheimer's disease (with hypometabolism, atrophy, and amyloid accumulation). The authors hypothesize that longstanding cerebral metabolic patterns across the lifespan may predispose to Alzheimer's disease neuropathology.
89. Sperling R, Chua E, Cocchiarella A, et al. Putting names to faces: successful encoding of associative memories activates the anterior hippocampal formation. Neuroimage 2003; 20:1400-1410.
90. Smith CD, Andersen AH, Kryscio RJ, et al. Women at risk for AD show increased parietal activation during a fluency task. Neurology 2002; 58:1197-1202.
91. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343:450-456.
92. Bondi MW, Houston WS, Eyler LT, et al. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 2005; 64:501-508.
93. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379-2388.
94. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319. The first report in humans of in-vivo fibrillar amyloid imaging using a PET radioligand, proving the principle that Alzheimer neuropathology can be detected with imaging in living human patients with clinical Alzheimer's disease.